| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Alpha Tau Medical Ltd.$12.71
-0.42 (-3.24%)
D 28Pipeline Score MedTech · Clinical
Market Cap
883.62 M
EPS
-0.66
P/E Ratio
-
Value Trade
33.78 M
-2.14 %
Week
25.03 %
1 Month
39.25 %
3 Month
192.71 %
6 Month
4.04 %
5 Year
402 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
640.47 K
52 Week Range
2.81 - 11.62
% held by Insiders
20.81 %
% held by Institutions
4.86 %
Enterprise Value
817.73 M
Total Shares
88.08 M
Short %
3.02 %
Float Shares
46.86 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D28
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 31%
Micro Cap (rank 630 of 911)
Percentile RankAlpha Tau Medical Ltd. faces pipeline headwinds (28/100), with 1 assets in development.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Alpha DaRT Breakthrough | pancreatic ductal adenocarcinoma | Phase 1/2 | 2026-06-01 | median overall survival (mOS) of 11.2 months in metastatic disease; median overall survival (mOS) of 11.1 months in locally advanced disease; historical data shows ~4 - 6 months for metastatic patients; historical data shows ~9 months for locally advanced patients; median overall survival of 17.0 months in metastatic disease for patients who had received one prior line of chemotherapy; median overall survival of 13.8 months in locally advanced disease for patients who had received one prior line of chemotherapy; treatment-associated adverse events reported in 36% of subjects; Grade 3 events in 9%; no treatment-related deaths; no chronic toxicity Read More | Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, mi Read More | |
Alpha DaRT Breakthrough | pancreatic ductal adenocarcinoma | Phase 1/2 | 2026-06-01 | median overall survival (mOS) of 11.2 months in metastatic disease; median overall survival (mOS) of 11.1 months in locally advanced disease; historical data shows ~4 - 6 months for metastatic patients; historical data shows ~9 months for locally advanced patients; median overall survival of 17.0 months in metastatic disease for patients who had received one prior line of chemotherapy; median overall survival of 13.8 months in locally advanced disease for patients who had received one prior line of chemotherapy; treatment-associated adverse events reported in 36% of subjects; Grade 3 events in 9%; no treatment-related deaths; no chronic toxicity Read More | Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, mi Read More | |
Alpha DaRT Breakthrough | pancreatic ductal adenocarcinoma | Phase 1/2 | 2026-06-01 | median overall survival (mOS) of 11.2 months in metastatic disease; median overall survival (mOS) of 11.1 months in locally advanced disease; historical data shows ~4 - 6 months for metastatic patients; historical data shows ~9 months for locally advanced patients; median overall survival of 17.0 months in metastatic disease for patients who had received one prior line of chemotherapy; median overall survival of 13.8 months in locally advanced disease for patients who had received one prior line of chemotherapy; treatment-associated adverse events reported in 36% of subjects; Grade 3 events in 9%; no treatment-related deaths; no chronic toxicity Read More | Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, mi Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DRTS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DRTS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DRTSOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Pharmaceuticals has announced its inclusion in the Russell 2000 and 3000 indexes, which is expected to enhance its visibility and shareholder base. The company has also significantly repaid its Scilex loan, recovering approximately $118 million of the $99.5 million loan. Additionally, Oramed's balance sheet is strong, with total cash and assets around $270 million as of March 31, 2026.
Read more →DRTSAlpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control - Following the pre-specified interi
Alpha Tau Medical has received FDA clearance to resume patient enrollment in its REGAIN trial for recurrent glioblastoma, following positive interim results showing 100% local disease control among initial patients. The trial will now include two additional U.S. academic cancer centers, which will broaden geographic access and expertise. The interim results also revealed a 67% complete response rate, highlighting the potential of Alpha DaRT as a transformative treatment option. This regulatory success marks a continuation of the company's promising journey in glioblastoma treatment development.
Read more →DRTS▲ +18.5%on this news
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT Therapy to U.S. Urological Cancer Patients - Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolma
Alpha Tau Medical Ltd. and Tolmar International Ltd. have announced a strategic partnership to commercialize Alpha DaRT therapy for prostate cancer in the United States. Under this agreement, Tolmar will have exclusive rights to market the therapy, supported by a $15 million manufacturing investment and a $20 million equity infusion. The collaboration emphasizes the importance of developing alternatives for prostate cancer treatment and has the potential to significantly impact patient care. Additionally, there is an option for Tolmar to expand commercialization into bladder cancer, subject to meeting certain criteria.
Read more →DRTS▼ -10.8%on this newsshared move
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, mi
Alpha Tau Medical announced promising overall survival results for its Alpha DaRT treatment for pancreatic cancer, presented at the 2026 ASCO Annual Meeting. A pooled analysis from three Phase I/II studies showed significant median overall survival improvements in comparison to historical chemotherapy data. The treatment demonstrated a favorable safety profile with no chronic toxicity or treatment-related deaths reported. Following these results, Alpha Tau aims to continue its clinical trials for Alpha DaRT as a complementary therapy alongside front-line chemotherapy.
Read more →DRTSAlpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update - Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complet
Alpha Tau Medical Ltd. reported its first quarter 2026 financial results, highlighting significant progress in its clinical trials, including 100% local disease control in the REGAIN trial for recurrent glioblastoma and 67% complete response rate. The company also announced completion of patient enrollment in its pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma. Despite a net loss of $22.9 million, Alpha Tau maintains a solid cash balance of $80.2 million to support its ongoing research and development efforts. The growing recognition of the company's clinical data at major conferences further underscores its potential in oncology.
Read more →DRTSAlpha Tau to Participate in May Investor Conferences
Alpha Tau Medical Ltd. has announced that its CFO, Raphi Levy, will participate in several investor conferences throughout May 2026. These conferences include the H.C. Wainwright 4th Annual BioConnect Investor Conference and the Rothschild & Co Redburn Radiopharma Conference, among others. Mr. Levy will be available for one-on-one meetings at all events, suggesting a proactive approach to investor relations. The participation indicates the company's ongoing efforts to engage with potential investors and promote its innovative alpha-radiation cancer therapy, Alpha DaRT.
Read more →DRTS▲ +21.5%on this news
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
Alpha Tau Medical announced promising interim results from its U.S. trial of Alpha DaRT for recurrent glioblastoma, showing 100% local disease control and a 67% complete response rate among the first three patients treated. The trial, which aims to provide new treatment options for this challenging cancer, reported a favorable safety profile with only one serious adverse event, now resolved. A conference call is scheduled to discuss these findings further.
Read more →DRTS▲ +21.5%on this newsshared move
Revolutionary Alpha-Emitters Radiotherapy: Brain Tumors 1 2 This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested partie
Alpha Tau Medical Ltd. has presented information on its Alpha DaRT technology, which employs alpha-emitting radiotherapy for treating brain tumors and other cancers. The presentation outlines the mechanism of action and discusses upcoming milestones and clinical trials. However, it also emphasizes the significant risks and uncertainties in clinical development and regulatory approval. The company disclaims liability for information reliability, leaving potential investors cautious about making decisions based on this information.
Read more →DRTS▲ +8.4%on this news· ran to +32% by day 1shared move
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT to Treat Recurrent Cutaneous Squamous Cell Carcinoma - First U.S. pivotal study for Alpha
Alpha Tau Medical Ltd. has successfully completed patient enrollment in its ReSTART pivotal trial, assessing the Alpha DaRT treatment for recurrent cutaneous squamous cell carcinoma (cSCC). This milestone is significant in the company's aim for FDA pre-market approval, leveraging a robust backdrop of data from prior studies in various countries. With 88 patients enrolled, the study will now advance to follow-up phases to evaluate key efficacy and safety endpoints. The trial is notable for addressing significant unmet needs in patients whose cancer has returned after conventional treatment methods have failed.
Read more →DRTS▲ +8.4%on this news· ran to +32% by day 1shared move
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma Jerusalem
Alpha Tau Medical Ltd. announced plans to host a conference call on May 11, 2026, to discuss interim clinical results from the first three patients treated for recurrent glioblastoma as part of its REGAIN trial. This innovative approach utilizes the company's Alpha DaRT technology, which delivers targeted alpha-radiation to tumors. The trial aims to evaluate treatment feasibility and safety specifically for patients not eligible for surgical resection. The study is part of a push for new therapeutic options in the challenging landscape of brain cancer treatment.
Read more →DRTSAlpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute
Alpha Tau Medical Ltd. has successfully treated the first pancreatic cancer patient in Italy using its Alpha DaRT therapy at the University of Verona's Pancreas Institute. This marks a significant milestone as it is the first protocol worldwide to allow both endoscopic ultrasound and percutaneous delivery methods. The study aims to provide new treatment options for patients with locally advanced pancreatic cancer, reflecting Alpha Tau's commitment to expanding its global clinical program.
Read more →DRTSAlpha Tau Announces Upcoming Podium Presentation at the AHNS 12 th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT Head and Neck Cancer Combination with Pembrolizumab - Abstract fr
Alpha Tau Medical Ltd. has announced that an abstract showcasing the results of their innovative therapy, Alpha DaRT, in combination with pembrolizumab has been accepted for podium presentation at the AHNS 12th International Conference on Head and Neck Cancer scheduled for July 2026. This study focuses on elderly patients suffering from advanced head and neck cancers, a population with notably limited treatment options. The combination therapy is expected to enhance immune activation without increasing treatment toxicity, presenting a promising advancement in cancer care. The selection for podium presentation underscores the significance of their findings in the field of oncology.
Read more →DRTS▼ -11.8%on this newsshared move
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Alpha Tau Medical Ltd. announced a 100% local disease control rate in pancreatic cancer patients treated with Alpha DaRT in two first-in-human trials. The results, presented at DDW 2026, showed a favorable safety profile with minimal adverse events. The treatment is designed for easy integration into standard procedures, highlighting its potential in oncology.
Read more →DRTSAlpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
Alpha Tau Medical announced that its abstract on Alpha DaRT for pancreatic cancer has been accepted at the ASCO Annual Meeting. This pooled analysis includes data from 58 patients across three studies, showcasing promising safety and efficacy. The acceptance reflects increasing recognition of Alpha Tau's clinical program and its innovative approach to treating pancreatic cancer.
Read more →DRTSAlpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane (Nab-Paclitaxel)
Alpha Tau Medical Ltd. has received FDA approval for an Investigational Device Exemption (IDE) supplement, which allows the expansion of its IMPACT study. This enhancement will enable the inclusion of additional patients receiving gemcitabine and nab-paclitaxel, increasing the trial size from 30 to 40 patients. The study focuses on assessing the safety and efficacy of Alpha DaRT in combination with chemotherapy for newly diagnosed pancreatic cancer patients. Alpha Tau aims to meet the pressing medical needs surrounding pancreatic cancer treatment through this clinical program.
Read more →DRTSAlpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
Alpha Tau Medical has successfully treated the first patient in the ACAPELLA trial, which evaluates the Alpha DaRT therapy combined with capecitabine for inoperable locally advanced pancreatic cancer. This trial aims to provide a treatment path for patients who have completed first-line chemotherapy but lack further options. The procedure was performed at CHU Grenoble Alpes, marking a significant step in Alpha Tau's clinical expansion in Europe.
Read more →DRTS▲ +7.9%on this news
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
Alpha Tau Medical Ltd. has announced that its abstract on Alpha DaRT for pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026. This marks a significant milestone as it is the first time results of Alpha DaRT in pancreatic cancer patients will be presented at a major gastroenterology conference. The presentation will be led by Dr. Harold Jacob and will highlight the feasibility, safety, and tumor control of the treatment.
Read more →DRTSAlpha Tau to Present at Sidoti March Virtual Small Cap Conference
Alpha Tau Medical Ltd. (Nasdaq: DRTS) has announced that its CFO, Raphi Levy, will present at the Sidoti Virtual Small Cap Conference, scheduled for March 18-19, 2026. The event will highlight the company's innovative alpha-radiation cancer therapy, Alpha DaRT, which aims to treat solid tumors while sparing surrounding healthy tissue. Attendees will have the opportunity to schedule one-on-one investor meetings with Mr. Levy, further facilitating discussions about the company's developments.
Read more →DRTSAlpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update - Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data fr
Alpha Tau Medical Ltd. announced its full year 2025 financial results and a corporate update, highlighting significant recent achievements including the receipt of marketing approval in Japan and the approval of five clinical trials in the U.S. The company reported a net loss of $42.6 million, which was higher than the previous year's loss, primarily due to rising research and development costs. They noted a strong cash position of $76.9 million, which supports ongoing clinical advancements and preparations for commercialization. Upcoming milestones include progress in multiple pivotal trials in the U.S.
Read more →DRTSAlpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
Alpha Tau Medical has received marketing approval from Japan's Ministry of Health for its Alpha DaRT therapy, marking the first authorization outside Israel. This approval initiates a post-market surveillance study to evaluate the therapy's safety and effectiveness in real-world settings. The company aims to collaborate with Japanese clinicians to generate further clinical data and explore reimbursement strategies.
Read more →DRTSAlpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
Alpha Tau Medical Ltd. has announced an active clinical agenda for 2026, with five concurrent trials in the U.S. focusing on various cancers, including pancreatic and glioblastoma. The company is also preparing for potential regulatory approval in Japan for its Alpha DaRT therapy. Positive interim results from ongoing studies bolster confidence in the therapy's efficacy, while the company continues to enhance its manufacturing capabilities.
Read more →DRTS▲ +11.9%on this news· ran to +33% by day 3
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT Study - Final results from f
Alpha Tau Medical Ltd. has announced positive results from their Alpha DaRT pancreatic cancer study, demonstrating an 81% disease control rate. The findings highlight the therapy's potential for immune preservation and significant efficacy compared to conventional treatments. These results will be presented at the ASCO GI 2026 Symposium, further validating the potential of Alpha DaRT in treating pancreatic ductal adenocarcinoma. The company is also exploring further clinical trials in the US, indicating a commitment to advancing this innovative therapy.
Read more →DRTS▲ +8.1%on this news· ran to +33% by day 3shared move
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Alpha Tau Medical Ltd. has submitted its first pre-market approval module to the FDA for Alpha DaRT, aimed at treating recurrent cutaneous squamous cell carcinoma. This submission is part of a flexible modular approach granted by the FDA, allowing ongoing feedback. The company is also conducting the ReSTART pivotal study, expected to complete patient recruitment by Q1 2026.
Read more →DRTSAlpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference - The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones - JERUSALEM, Decemb
Alpha Tau Medical Ltd. announced that CEO Uzi Sofer and CFO Raphi Levy will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026. The presentation will review the company's recent achievements and outlook for future data milestones. The event will take place at the Westin St. Francis in San Francisco, CA, and will include institutional investor meetings. Alpha Tau focuses on innovative cancer treatment solutions, particularly its Alpha DaRT therapy.
Read more →DRTS▲ +8.7%on this news· ran to +30% by day 1
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University - First patient in the world treated with Alpha DaRT in the
Alpha Tau Medical Ltd. has successfully treated the first patient in its U.S. clinical trial for recurrent glioblastoma using its Alpha DaRT technology. The treatment has the potential to fill a critical gap in local therapies for this aggressive cancer, which has a low average survival rate. The pilot study is part of a broader strategy supported by the FDA to accelerate treatment availability for patients in need. The procedure demonstrated excellent feasibility, but the trial is limited in scope and faces challenges like regulatory approvals and funding.
Read more →DRTSAlpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
Alpha Tau Medical Ltd. announced that two abstracts regarding its Alpha DaRT therapy for pancreatic cancer have been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium. The studies focus on the feasibility and immune response dynamics of the therapy. CEO Uzi Sofer expressed excitement about the continued recognition of their work in this critical area of cancer treatment.
Read more →DRTSAlpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
Alpha Tau Medical Ltd. has received FDA approval to initiate a pilot study using its Alpha DaRT technology for patients with locally recurrent prostate cancer. This marks the company's fifth active Investigational Device Exemption in the U.S. The trial will assess the safety and efficacy of the treatment, with promising results from prior studies in Israel. The study aims to provide a new local salvage therapy option for patients facing limited alternatives.
Read more →DRTSAlpha Tau to Participate in December Investor Conferences
Alpha Tau Medical Ltd. (NASDAQ: DRTS) will be represented by CFO Raphi Levy at two investor conferences in December 2025. These events include the 37th Annual Piper Sandler Healthcare Conference and Sidoti's Year End Virtual Investor Conference, where Levy will also be available for individual investor meetings. The company focuses on the development of Alpha DaRT, an innovative cancer treatment using alpha-radiation therapy, indicating potential for attracting investor interest and funding.
Read more →DRTS▼ -5.7%on this news
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study - - Newly received radioactive material l
Alpha Tau Medical Ltd. (NASDAQ: DRTS) reported its third quarter 2025 financial results, highlighting ongoing advancements in its Alpha DaRT pancreatic cancer treatments through a U.S. multi-center pilot study. The company secured a new radioactive material license for its facility in New Hampshire and is preparing for regulatory submissions in multiple markets. Despite a significant cash position of $75.9 million, Alpha Tau reported a net loss of $30.5 million for the year-to-date period, illustrating the financial pressures it faces.
Read more →DRTSAlpha Tau to Participate at Jefferies Global Healthcare Conference in London
Alpha Tau Medical Ltd. will participate in the Jefferies Global Healthcare Conference in London on November 18-19, 2025. CFO Raphi Levy will be available for one-on-one investor meetings during the event. The company focuses on developing Alpha DaRT, a novel alpha-radiation therapy for solid tumors.
Read more →DRTS▲ +5%on this news
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
Alpha Tau Medical Ltd. has received a radioactive material license for its manufacturing facility in New Hampshire, marking a key step towards commercial readiness. The facility aims to produce Alpha DaRT treatments by 2026, following the completion of its first construction phase. This development is expected to enhance Alpha Tau's operational capabilities and support its clinical trial initiatives.
Read more →DRTSAlpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
Alpha Tau Medical has successfully treated the first patient in its U.S. multi-center pilot study, IMPACT, which evaluates Alpha DaRT combined with chemotherapy for pancreatic cancer. This study targets patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma, addressing a significant unmet medical need. The trial aims to assess the safety and efficacy of this innovative treatment approach.
Read more →DRTSAlpha Tau to Participate in Five September Investor Conferences
Alpha Tau Medical Ltd. announced its participation in five investor conferences in September 2025. CFO Raphi Levy will present the company's innovative alpha-radiation cancer therapy, Alpha DaRT, which aims to treat solid tumors while minimizing damage to surrounding healthy tissue. The company anticipates key clinical trial data in the coming years, although it faces various operational risks.
Read more →DRTS▼ -8.7%on this news
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Alpha Tau Medical Ltd. reported its second quarter 2025 financial results, highlighting FDA approval for a pilot study of its Alpha DaRT therapy in glioblastoma patients. The company has secured $36.9 million in funding and plans to initiate several clinical trials in the U.S. and Europe. Despite a net loss of $18.8 million, Alpha Tau maintains a strong cash position to support its clinical and commercial activities.
Read more →DRTS▲ +5%on this newsshared move
ALPHA TAU MEDICAL LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Consolidated Balance Sheets 3-4 Interim Consolidated Statements of Operations 5
Alpha Tau Medical Ltd. has released its interim consolidated financial statements as of June 30, 2025, highlighting significant financial losses. The company incurred a net loss of $18,805 during the six-month period, and its accumulated deficit has increased to $166,314. Furthermore, negative cash flows from operating activities totaled $14,612, suggesting ongoing operational difficulties. The financial statements outline a continued emphasis on the development of their oncology therapeutic technologies, yet reflect a substantial financial burden.
Read more →DRTSAlpha Tau to Present at Jefferies Global Healthcare Conference
Alpha Tau Medical Ltd. announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025. The company focuses on the development of Alpha DaRT, an innovative alpha-radiation therapy for solid tumors. Investors can schedule one-on-one meetings with Levy during the event.
Read more →DRTS▲ +11.1%on this news
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update - Interim Jan-2025 results from three trials of Alpha DaRT in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium
Alpha Tau Medical Ltd. reported positive financial results and a corporate update for the first quarter of 2025, highlighting the success of their Alpha DaRT therapy in clinical trials for pancreatic cancer, with over 90% disease control achieved. The company received FDA approvals for multiple clinical studies and completed significant financing to support their operations. However, they also noted an increased net loss and R&D expenses compared to the previous year, signaling ongoing financial challenges. Alpha Tau aims to expand its clinical trial program and manufacturing capabilities with these recent developments.
Read more →DRTSAlpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
Alpha Tau Medical Ltd. has appointed Nadav Kidron, CEO of Oramed Pharmaceuticals, to its Board of Directors. This strategic move follows a recent investment from Oramed. Kidron's extensive experience in the life sciences sector is expected to enhance Alpha Tau's efforts in commercializing its innovative cancer therapy, Alpha DaRT.
Read more →DRTSAlpha Tau to Participate in May Investor Conferences JERUSALEM
Alpha Tau Medical Ltd. announced its participation in two upcoming investor conferences in May 2025. CFO Raphi Levy will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference and will also hold meetings at the Lytham Partners Spring 2025 Investor Conference. These events will provide an opportunity for investors to engage with the company regarding its alpha-radiation cancer therapy, Alpha DaRT, which targets solid tumors.
Read more →DRTSAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Alpha Tau Medical Ltd. has closed a $36.9 million registered direct offering, selling over 14 million shares to an affiliate of Oramed Pharmaceuticals. The funds will support corporate purposes, including R&D and manufacturing expansion. Additionally, Alpha Tau has entered a strategic alliance with Oramed for investor and public relations services. Both companies express optimism about future advancements.
Read more →DRTSAlpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma JERUSALEM
Alpha Tau Medical Ltd. has received FDA approval to initiate a pilot study evaluating the safety and feasibility of its Alpha DaRT technology for patients with recurrent glioblastoma. This innovative alpha-radiation therapy is designed for tumors that are not amenable to surgery, thus providing a potential new treatment avenue for this aggressive cancer. The trial will involve up to ten patients who have previously undergone radiation therapy. This approval follows the FDA's recognition of the promising potential of the Alpha DaRT technology in treating difficult cases of glioblastoma.
Read more →DRTSAlpha Tau Announces Full Year 2024Financial Results and Provides Corporate Update - Interim results from three trials exploring the use of Alpha DaRT in treating pancreatic cancer showing high disease control rate, impre
Alpha Tau Medical Ltd. reported its full year 2024 financial results and provided an update on corporate activities, highlighting positive interim results from three trials of their Alpha DaRT therapy for pancreatic cancer. The results demonstrated high disease control and overall survival rates, alongside increasing safety profiles. The company received FDA approval for U.S. pilot studies and was accepted into an advisory program to expedite market access. Despite a reported net loss, Alpha Tau maintains a strong cash position to support its operations over the next two years.
Read more →DRTSAlpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Alpha Tau Medical has reported positive interim results from trials of its Alpha DaRT therapy for pancreatic and head and neck cancers. The therapy demonstrated a high disease control rate and significantly outperformed historical benchmarks when combined with Keytruda. Furthermore, the FDA granted the company approval for several new clinical trials and the Total Product Life Cycle Advisory Program. Despite the positive clinical findings and financial support extending its operational runway, the company reported an increased net loss for the year.
Read more →DRTSAlpha Tau to Participate in March Investor Conferences JERUSALEM
Alpha Tau Medical Ltd., a company focused on innovative alpha-radiation cancer therapies, announced its participation in several investor conferences in March 2025. CFO Raphi Levy will present at the Investor Summit, Oppenheimer's Annual Healthcare MedTech & Services Conference, and the Sidoti Small Cap Conference. These virtual presentations reflect the company's efforts to enhance investor engagement and promote its Alpha DaRT technology for solid tumors. Additionally, Levy will be available for one-on-one investor meetings to discuss Alpha Tau's strategic initiatives and developments.
Read more →DRTSAlpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification JERUSALEM
Alpha Tau Medical Ltd. announced that it has received Medical Device Single Audit Program (MDSAP) certification for its manufacturing facility in Jerusalem. This achievement signals the company's commitment to quality and regulatory compliance in the global expansion of its alpha-radiation cancer therapy, Alpha DaRT. The MDSAP certification is expected to streamline the auditing process across multiple markets, potentially expediting the commercialization of Alpha DaRT. CEO Uzi Sofer highlighted the milestone's significance for enhancing manufacturing capabilities and facilitating the treatment of solid tumors.
Read more →DRTSAlpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
Alpha Tau Medical Ltd. has received FDA approval for an Investigational Device Exemption (IDE) supplement, allowing the company to expand its pilot clinical trial for Alpha DaRT therapy to include a total of 30 patients with pancreatic cancer. This trial will now include an additional cohort for patients with locally advanced disease. The expansion follows promising preliminary data on disease control and survival rates. The trial is set to take place at up to 10 clinical sites across the U.S.
Read more →DRTSAlpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease JERUSALEM, February 3 rd , 2025
Alpha Tau Medical Ltd. announced FDA approval of an Investigational Device Exemption supplement, allowing them to expand their pilot trial of Alpha DaRT to 30 patients with pancreatic cancer. The expansion includes an additional cohort for patients with locally advanced pancreatic cancer, increasing participant numbers at up to 10 clinical sites across the U.S. CEO Uzi Sofer expressed optimism about the data released on disease control and survival rates, indicating progress in exploring effective treatments for this challenging condition.
Read more →DRTSAlpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day - High disease control rate and strong interim safety results observed in pancreatic cancer patients across thre
Alpha Tau Medical Ltd. (NASDAQ: DRTS) announced promising interim data from various clinical trials, showcasing the safety and efficacy of its alpha-radiation therapy, Alpha DaRT. An Investigational Device Exemption from the FDA allows for a new pilot study combining Alpha DaRT with chemotherapy in metastatic pancreatic cancer. The company also received approval from France's Ministry of Health for a multicenter trial involving Alpha DaRT and capecitabine for locally advanced pancreatic cancer. Additionally, data from a combination study with pembrolizumab indicated a strong systemic response among treated patients with head and neck cancer.
Read more →DRTSAlpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day JERUSALEM, December 18 th , 2024 -- Alpha Tau Medical Ltd. ( Alpha Tau , or the "Company") (NASDAQ: DRTS, DRTS
Alpha Tau Medical Ltd. has announced that an abstract detailing interim findings from their pancreatic cancer trials has been accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium. This presentation marks a significant milestone for the company, as it will showcase their alpha-radiation therapy, Alpha DaRT. Additionally, Alpha Tau is set to host an R&D Update Day where further data from their trials will be discussed, which includes ongoing studies in other cancer types. The company's CEO expressed optimism about sharing their research with experts in the field.
Read more →DRTSAlpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor JERUSALEM, December 17 th ,2024-- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), (
Alpha Tau Medical Ltd. has appointed Maya Netser to its Board of Directors following its Annual General Meeting. Meir Jakobsohn, a long-standing board member, has chosen not to seek re-election but will continue as an advisor. Netser, with over 25 years of experience in technology and life sciences, is expected to contribute significantly to the company's growth, especially as it expands its Alpha DaRT cancer therapy focus. CEO Uzi Sofer expressed confidence in her ability to support the company's mission.
Read more →DRTSAlpha Tau to Present at the 43 rd Annual J.P. Morgan Healthcare Conference - The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones - JERUSALEM
Alpha Tau Medical Ltd. has announced that CEO Uzi Sofer and CFO Raphi Levy will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The presentation will focus on the company's recent achievements and outline their upcoming data milestones regarding their innovative alpha-radiation cancer therapy, Alpha DaRT. The event, taking place in San Francisco, will also include opportunities for one-on-one meetings with institutional investors. The presentation highlights Alpha Tau's commitment to advancing its research on solid tumors.
Read more →DRTSAlpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Alpha Tau Medical Ltd. will present an overview of its operations and updates at the J.P. Morgan 43rd Annual Healthcare Conference on January 16, 2025, in San Francisco. CEO Uzi Sofer and CFO Raphi Levy will lead the presentation and host individual investor meetings. The company's focus is on developing Alpha DaRT, a novel alpha-radiation therapy for treating solid tumors. This event provides an opportunity for the company to engage with institutional investors and highlight its progress in oncology therapeutics.
Read more →DRTSAlpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium JERUSALEM, December 6 th , 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the inno
Alpha Tau Medical Ltd. announced its participation in the upcoming Ladenburg Oncology Innovators & Investors Symposium. CFO Raphi Levy will present the company's innovative treatment, Alpha DaRT, which is designed to treat solid tumors. The event is scheduled for December 12, 2024, and will take place virtually. This symposium provides an opportunity for investors to learn more about Alpha Tau's advancements in oncology therapeutics.
Read more →DRTSAlpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Alpha DaRT accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market a
Alpha Tau Medical Ltd. reported its third quarter 2024 financial results, demonstrating significant advancements in its Alpha DaRT technology. The FDA has accepted Alpha DaRT into its Total Product Life Cycle Advisory Program to enhance market access for patients with recurrent glioblastoma multiforme. Additionally, Alpha Tau has treated the first patient in a lung cancer study and received FDA approval to initiate a study for treating recurrent cutaneous squamous cell carcinoma in immunocompromised patients. Despite recording a net loss, the company's CEO expressed optimism regarding the ongoing trials and future data releases.
Read more →DRTSAlpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36 th Annual Healthcare Conference JERUSALEM, November 13 th , 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASD
Alpha Tau Medical Ltd. announced that its CFO, Raphi Levy, will participate in two upcoming healthcare conferences: Citi's 2024 Global Healthcare Conference on December 3 and Piper Sandler's 36th Annual Healthcare Conference on December 5, 2024. These events will feature one-on-one meetings and a fireside chat format, providing Alpha Tau an opportunity to showcase its innovative alpha-radiation cancer therapy, Alpha DaRT. The company's focus on solid tumor treatments using advanced radiotherapy techniques positions it as a noteworthy player in oncology therapeutics.
Read more →DRTSAlpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT for Patients with Recurrent Glioblastoma Multiforme JERUSALEM
Alpha Tau Medical Ltd. has been accepted into the FDA's Total Product Life Cycle Advisory Program to expedite market access for its Alpha DaRT therapy aimed at patients with recurrent glioblastoma multiforme. This acceptance follows the receipt of Breakthrough Device Designation from the FDA, which is crucial for advancing the product's commercialization. The TAP program provides strategic guidance to help reduce the uncertainties associated with bringing new medical devices to market. The company is optimistic about this opportunity, as there is a significant need for innovative therapies in treating glioblastoma, a condition with low survival rates.
Read more →DRTSAlpha Tau Treats First Patient with Recurrent Lung Cancer JERUSALEM
Alpha Tau Medical Ltd. has treated its first patient with recurrent lung cancer using its alpha-radiation therapy, Alpha DaRT, during a clinical trial at Hadassah Medical Center in Jerusalem. This trial will involve up to ten patients and focuses on assessing the safety and efficacy of the therapy while allowing concurrent treatments like chemotherapy. The approach aims to precisely target tumor cells, potentially offering new options for patients with limited treatment possibilities. Initial results from this trial could pave the way for wider application of Alpha DaRT in treating lung cancer.
Read more →DRTSAlpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT in Immunocompromised Patients with Recurrent cSCC -Trial to focus on particularly vulnerable subset of patients,
Alpha Tau Medical Ltd. has received FDA approval for an Investigational Device Exemption (IDE) to initiate a multi-center study using their Alpha DaRT therapy for patients with recurrent cutaneous SCC who are immunocompromised. The study will enroll up to 28 patients across eight U.S. institutions, focusing on treatment efficacy and safety. This clinical effort is a response to strong interest from clinicians in treating this vulnerable patient population, which has limited treatment options available. The results could provide valuable data for using Alpha DaRT in a significant cancer patient subset.
Read more →DRTSAlpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
Alpha Tau Medical Ltd. announced its participation in several upcoming investor conferences, including the H.C. Wainwright Global Investment Conference and the Sidoti Small-Cap Virtual Investor Conference. CFO Raphi Levy will present a corporate overview and is available for individual meetings during these events. These appearances are part of the company's strategy to maintain investor engagement and share updates on its innovative alpha-radiation cancer therapy, Alpha DaRT.
Read more →DRTSAlpha Tau to Participate in the H.C. Wainwright 26 th Annual Global Investment Conference , the Sidoti Small-Cap Virtual Investor Conference , the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the
Alpha Tau Medical Ltd. (NASDAQ: DRTS) has announced its participation in several upcoming investor conferences, including the H.C. Wainwright 26th Annual Global Investment Conference and the Sidoti Small-Cap Virtual Investor Conference. CFO Raphi Levy will present a corporate overview and be available for one-on-one investor meetings. The events are scheduled between September and October 2024, aiming to enhance the company's visibility and engagement with investors related to its novel alpha-radiation cancer therapy, Alpha DaRT.
Read more →DRTSAlpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update - First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of lon
Alpha Tau Medical Ltd. reported its financial results for the second quarter of 2024, highlighting significant advancements in its alpha-radiation cancer therapy. The company successfully treated its first patient for liver metastases from colorectal cancer, showcasing promising response rates. In addition, a publication in the Cancers journal presented favorable long-term safety and efficacy data for Alpha DaRT, reinforcing its potential in treating difficult tumors. Despite a net loss for the period, Alpha Tau's cash reserves are expected to sustain operations for at least two years, indicating a solid financial foundation.
Read more →DRTSALPHA TAU MEDICAL LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Consolidated Balance Sheets 2 - 3 Interim Consolidated Statements of Operations
Alpha Tau Medical Ltd. has released its interim consolidated financial statements for the six months ending June 30, 2024. The company reported a net loss of $15,350, with total liabilities decreasing slightly to $22,031. Cash and cash equivalents significantly declined to $2,763, reflecting continued financial pressure. Despite the ongoing challenges, the company remains focused on developing its Alpha DaRT technology for cancer treatment.
Read more →DRTSAlpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers The pooled analysis included data from 4 international clinical trials spanning an ar
Alpha Tau Medical Ltd. announced the publication of long-term safety and efficacy data from its Alpha DaRT treatment for superficial cancers in the journal 'Cancers'. This pooled analysis from four international clinical trials demonstrated impressive outcomes, including a 99% overall response rate and 89% complete response rate in treated lesions. Notably, there were no moderate or severe long-term toxicities observed, and the two-year local recurrence-free survival rate was estimated at 77%. The study highlights Alpha DaRT's potential for providing long-term disease control for challenging cancer indications.
Read more →DRTSAlpha Tau to Present at the Jefferies Global Healthcare Conference JERUSALEM
Alpha Tau Medical Ltd. is scheduled to present at the Jefferies Global Healthcare Conference on June 5, 2024. The company's CFO, Raphi Levy, will provide a corporate overview and participate in one-on-one investor meetings. Alpha Tau specializes in alpha-radiation cancer therapy, focusing on the treatment of solid tumors through its technology, Alpha DaRT. This event may enhance investor interest and visibility for the firm as it seeks to advance its therapeutic offerings.
Read more →DRTSAlpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update - Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in
Alpha Tau Medical announced its first-quarter financial results for 2024, including a net loss of $8.0 million. The company showcased preclinical data indicating an abscopal immune effect in pancreatic cancer models at ESTRO 2024 and treated its first patient in a liver metastases study. They are actively recruiting for trials in the U.S., Canada, and Israel, capitalizing on ongoing developments in their alpha-radiation therapy, Alpha DaRT. With a solid cash reserve of $80.7 million, Alpha Tau aims to continue advancing its projects and is preparing for future product launches.
Read more →DRTSAlpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer JERUSALEM
Alpha Tau Medical Ltd. has announced the treatment of its first patient with liver metastases from colorectal cancer using its innovative Alpha DaRT therapy during a safety and feasibility study at the McGill University Health Center in Montreal. The study aims to assess the safety, feasibility, and efficacy of Alpha DaRT in this indication, recruiting up to 10 patients. The initial goal is to surgically remove metastatic tumors while inserting Alpha DaRT sources into remaining tumors, followed by further surgical removal after liver regeneration. The company aims to expand Alpha DaRT's clinical applications beyond existing uses, driven by positive preclinical results.
Read more →DRTSAlpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow - Initial data demonstrates significant reduction in distant pancreatic cancer
Alpha Tau Medical Ltd. has presented promising preclinical data at the ESTRO 2024 Congress in Glasgow, showcasing the abscopal immune effect of its Alpha DaRT therapy on pancreatic cancer. The results indicate a significant reduction in growth rates of untreated distant tumors in murine models following the treatment of primary tumors with Alpha DaRT. The company plans to advance these findings into clinical trials for the treatment of pancreatic cancer, potentially in combination with immunotherapy, based on these encouraging preclinical insights.
Read more →DRTSAlpha Tau to Present at the Jefferies Radiopharma Innovation Summit JERUSALEM
Alpha Tau Medical Ltd. (NASDAQ: DRTS) announced that its CFO, Raphi Levy, will present a corporate overview at the Jefferies Radiopharma Innovation Summit on April 11, 2024. The presentation will include updates on their alpha-radiation cancer therapy, Alpha DaRT. This event offers a platform for network opportunities through one-on-one meetings. Alpha DaRT aims to treat solid tumors effectively while preserving surrounding healthy tissues.
Read more →DRTSAlpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update - Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose res
Alpha Tau Medical announced its financial results for the full year 2023, reporting a net loss of $29.2 million. The company shared positive interim safety and feasibility results from its pancreatic cancer study in Montreal, indicating potential dose response. In addition, Alpha Tau is conducting its ReSTART pivotal trial for recurrent cutaneous squamous cell carcinoma across multiple centers in the U.S. and has submitted an application for regulatory approval in Japan. The company's financial position remains strong with $84.9 million in cash reserves.
Read more →DRTS▼ -6.1%on this news
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
Alpha Tau Medical Ltd. is set to participate in the Barclays 26th Annual Global Healthcare Conference on March 12-13, 2024, in Miami, FL. This event will feature one-on-one meetings, which may provide opportunities for investors to engage with the company's management. Alpha Tau is renowned for its alpha-radiation cancer treatment, Alpha DaRT, designed to target solid tumors while minimizing damage to surrounding tissue. The conference participation underscores the company's commitment to advancing its innovative therapy in the oncology sector.
Read more →DRTS▼ -6.1%on this news
Alpha Tau to Participate in Barclays 26 th Annual Global Healthcare Conference JERUSALEM
Alpha Tau Medical Ltd. announced its participation in the Barclays 26th Annual Global Healthcare Conference scheduled for March 12-13, 2024, in Miami, FL. The company, known for its alpha-radiation cancer therapy Alpha DaRT, will engage in one-on-one meetings during the event. This conference presents an opportunity for Alpha Tau to highlight its innovative treatment approach and connect with potential investors and partners.
Read more →DRTSAlpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Alpha Tau Medical Ltd. will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, and at the Biotech Showcase on January 8, 2024. The presentations will highlight promising interim results from their pancreatic cancer safety and feasibility trial, along with robust long-term data from four clinical trials. Investors will have opportunities for institutional meetings at both events, indicating a proactive approach to stakeholder engagement.
Read more →DRTSAlpha Tau to Present at the 42 nd Annual J.P. Morgan Healthcare Conference - The overview presentation will review some of the Company's recent achievements, including highly promising interim results from the Company's
Alpha Tau Medical Ltd. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, showcasing promising interim results from its pancreatic cancer safety trial. The company will also feature at the Biotech Showcase on January 8, 2024, where they will engage in institutional investor meetings. Alpha Tau's innovative alpha-radiation therapy, Alpha DaRT, aims to effectively treat solid tumors while minimizing damage to surrounding healthy tissue. The live presentations will be available for webcast, and recordings will be archived for further access.
Read more →DRTSAlpha Tau to Participate in Sidoti Small-Cap Conference JERUSALEM
Alpha Tau Medical Ltd. announced it will participate in the Sidoti Small-Cap Virtual Conference on December 7th, 2023. The management will present their innovative alpha-radiation cancer therapy, Alpha DaRT, along with engaging in one-on-one meetings. This event provides the company with a platform to raise awareness and potentially attract investment for their ongoing developments in treating solid tumors.
Read more →DRTSAlpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer - Interim data read-out of the first five treated patients demonstrated success
Alpha Tau Medical Ltd. announced encouraging interim results from their safety and feasibility trial of Alpha DaRT for advanced pancreatic cancer. Initial data from the first five patients treated revealed successful delivery of the therapy with no serious adverse events related to the product. Among these patients, two displayed stable disease responses while one achieved a partial response. Despite some patients' subsequent deaths, they were not linked to the treatment, leading to optimism regarding the potential efficacy of Alpha DaRT in further trials.
Read more →DRTSAlpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer Jerusalem
Alpha Tau Medical Ltd. has submitted a request for pre-market approval of its alpha-radiation therapy, Alpha DaRT, to Japan's PMDA. This submission follows the successful clinical trial results, which have demonstrated better than expected safety and efficacy in patients with recurrent head and neck cancer. There are ongoing discussions with major biopharmaceutical companies for potential partnerships, and the company aims to capitalize on the significant need for effective treatment in this indication within Japan, where over 10,000 new cases arise annually.
Read more →DRTSAlpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alo
Alpha Tau Medical (NASDAQ: DRTS) has reported its third-quarter financial results, highlighting significant progress in its treatment for pancreatic cancer with the first patient treated at Hadassah Medical Center in Israel. The company boasts a strong cash position of $90.1 million, which is expected to support operations for at least two years. Notably, Alpha Tau's recent feasibility trials have shown promising results, including high local recurrence-free survival rates. The appointment of former U.S. FDA Commissioner Stephen M. Hahn to their Scientific Advisory Board is a further step to bolster the company’s strategic initiatives.
Read more →DRTS▼ -5%on this news
Alpha Tau to Participate in November Investor Conferences JERUSALEM
Alpha Tau Medical Ltd. (DRTS) has announced its participation in several upcoming investor conferences, including the Emerging Growth Conference, Jefferies London Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference. These events will feature company presentations and one-on-one meetings with management, providing opportunities to discuss their innovative alpha-radiation therapy, Alpha DaRT, aimed at treating solid tumors. The company's involvement in these conferences demonstrates its commitment to maintaining investor relations and transparency about its developmental progress.
Read more →DRTSAlpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility JERUSALEM
Alpha Tau Medical Ltd. has signed a long-term lease for a new manufacturing facility in Hudson, New Hampshire, aimed at producing its innovative alpha-radiation cancer therapy, Alpha DaRT. The company anticipates that this site will enhance its manufacturing capacity significantly compared to its existing facility in Lawrence, Massachusetts. With plans to initiate production within two years, Alpha Tau is also expanding its operations in Israel, suggesting a robust growth strategy in response to rising clinician interest and market demand for its treatments.
Read more →DRTS▲ +5.1%on this news
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board JERUSALEM
Alpha Tau Medical Ltd. has appointed Stephen M. Hahn, M.D., the former U.S. FDA Commissioner, to its Scientific Advisory Board. Dr. Hahn, who has extensive experience in radiation oncology and cancer treatment, is expected to contribute greatly as the company progresses its Alpha DaRT technology and continues its pivotal ReSTART trial for recurrent squamous cell carcinoma of the skin. His expertise could be instrumental in broadening treatment applications to include other cancers. This partnership is viewed as a potential significant advancement in cancer therapy.
Read more →DRTSAlpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center JERUSALEM
Alpha Tau Medical Ltd. has announced the treatment of its first patient with advanced inoperable pancreatic cancer using its innovative alpha-radiation therapy, Alpha DaRT, in a clinical trial at Hadassah Medical Center in Jerusalem. The trial is aimed at patients who are not suitable for other existing treatments. The procedure was reported to be efficient, and executives expressed optimism about Alpha DaRT's potential to transform cancer treatment for patients facing limited options. Ongoing studies are in place to further evaluate the safety and efficacy of this treatment modality.
Read more →DRTSALPHA TAU MEDICAL LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Interim Consolidated Balance Sheets 2 - 3 Interim Consolidated Statements of Operations
Alpha Tau Medical Ltd. released its interim consolidated financial statements for the period ending June 30, 2023. The reports indicate a decrease in total current assets and an increase in accumulated deficit. While the company experienced a reduction in its net loss compared to the previous year, liabilities have risen significantly. Overall, the financial health of Alpha Tau Medical appears strained, with rising debts overshadowing some positive operational adjustments.
Read more →DRTSAlpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update -Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April-
Alpha Tau Medical reported second quarter 2023 financial results and corporate updates, highlighting the treatment of its first patient with advanced inoperable pancreatic cancer in a trial in Canada. The company noted a strong 89% complete response rate in earlier trials for skin and neck cancers, along with a 77% local recurrence-free survival rate over two years. Alpha Tau has a cash position of $94.4 million, projected to fund operations for at least two more years. The company also announced a land grant in Jerusalem for expanded manufacturing capacity, although it incurred a net loss of $16.9 million for the period.
Read more →DRTSAlpha Tau Medical to Participate in September Investor Conferences JERUSALEM
Alpha Tau Medical Ltd. has announced its participation in several upcoming investor conferences in September 2023, including the Citi's Annual BioPharma Conference and Emerging Growth Conference. The events will feature various formats such as 1-on-1 meetings and company presentations. The company's innovative alpha-radiation cancer therapy, Alpha DaRT, will be showcased, potentially gaining interest from investors and stakeholders. The company was founded in 2016 and focuses on treating solid tumors.
Read more →DRTSAlpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT - 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete res
Alpha Tau Medical Ltd. announced promising long-term outcomes from its Alpha DaRT treatment across multiple clinical trials involving patients with head and neck or skin tumors. The studies revealed an impressive 89% complete response rate in lesions treated with Alpha DaRT, while the two-year local recurrence-free survival rate reached 77%. Notably, no severe acute toxicities (grade 3 or higher) were observed, although some patients experienced mild grade 2 toxicities. The company expressed optimism about the treatment's effectiveness and plans to continue gathering data from ongoing clinical trials.
Read more →DRTSAlpha Tau Medical to Present at the Emerging Growth Conference on August 9 th , 2023 JERUSALEM
Alpha Tau Medical Ltd. announced that its CFO, Raphi Levy, will present at the Emerging Growth Conference on August 9th, 2023. The presentation will focus on the company's innovative cancer treatment technology, Alpha DaRT. This conference provides an opportunity for the company to engage with investors and increase awareness of its advancements in cancer therapy. An archived version of the presentation will be available for those unable to attend live.
Read more →DRTSAlpha Tau Medical to Participate in June Investor Conferences JERUSALEM
Alpha Tau Medical Ltd. will participate in several investor conferences in June, including the Jefferies Healthcare Conference and the Sidoti Small-Cap Virtual Conference. The company aims to raise awareness for its novel cancer therapy, Alpha DaRT, which targets solid tumors using alpha-radiation. These presentations will include opportunities for one-on-one meetings, emphasizing Alpha Tau’s engagement with the investment community. The company continues to focus on innovative treatment solutions developed by prominent researchers from Tel Aviv University.
Read more →DRTS▼ -6.8%on this newsshared move
Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update - Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March - - Treat
Alpha Tau Medical Ltd. reported its first quarter 2023 financial results, announcing significant advancements in its cancer treatment programs. A U.S. multicenter pivotal trial for recurrent cutaneous squamous cell carcinoma has been initiated, alongside promising safety and feasibility trials for pancreatic and liver cancers in Canada and the UK. Financial results revealed a net loss of $8.2 million but maintained a solid cash balance of $100.5 million, sufficient for the next two years of operations. The company aims to produce meaningful data from these trials in the upcoming years.
Read more →DRTSAlpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
Alpha Tau Medical Ltd. has initiated a clinical trial to evaluate Alpha DaRT treatment for squamous cell carcinoma of the vulva at Addenbrooke's Hospital, Cambridge. The study seeks to involve 10 participants and will focus on safety, feasibility, and treatment efficacy over a six-month follow-up period. The trial, which includes comprehensive assessments of treatment effects and patient quality of life, highlights Alpha Tau's commitment to addressing significant medical needs in oncology. The initial treatment represents a potential advancement in a historically challenging area of cancer care.
Read more →DRTS▲ +7.9%on this news
Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
Alpha Tau Medical Ltd. published positive results from its multicenter pilot trial of the Alpha DaRT therapy for recurrent or unresectable skin cancer in JAMA Network Open. The trial showed a 100% Complete Response rate at 12 weeks, with no serious adverse events reported. The study involved ten patients and demonstrated safety and efficacy, paving the way for the upcoming pivotal trial, ReSTART. Alpha Tau aims to rapidly recruit patients for further evaluation of this promising treatment.
Read more →DRTSAlpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day JERUSALEM
Alpha Tau Medical Ltd. announced that its CFO, Raphi Levy, will participate in a fireside chat at the Guggenheim Radiopharmaceuticals Day in New York City on May 15, 2023. The event will feature Alpha Tau's innovative alpha-radiation cancer therapy, Alpha DaRT. Mr. Levy is also scheduled for one-on-one investor meetings, potentially boosting interest in the company's developments.
Read more →DRTSAlpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial -First patient treated in the feasibility and safety study of intratumoral diffusing alpha radiation e
Alpha Tau Medical and the Jewish General Hospital (JGH) have commenced a clinical trial for their Alpha DaRT therapy, treating the first patient with advanced inoperable pancreatic cancer. This feasibility and safety study aims to evaluate the procedure's safety and efficacy, targeting patients whose tumors are deemed inoperable. The trial will recruit 30 participants, with a focus on measuring adverse events and the treatment's impact on biomarkers. Alpha Tau's CEO emphasized the trial as a strategic milestone for expanding Alpha DaRT applications in challenging cancer cases.
Read more →DRTS▲ +5.3%on this newsshared move
Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit JERUSALEM
Alpha Tau Medical Ltd. announced that Chief Financial Officer Raphi Levy will present at the Jefferies Radiopharma Innovation Summit in New York City on April 3, 2023. This event highlights the company's innovative alpha-radiation cancer therapy, Alpha DaRT, aimed at treating solid tumors. In addition to the presentation, Levy will also be available for individual investor meetings, providing an opportunity to discuss the company's developments further.
Read more →DRTS▼ -7.4%on this news
Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank JERUSALEM
Alpha Tau Medical Ltd. announced that it has no financial ties or accounts with Silicon Valley Bank, assuring investors that the recent developments regarding the bank will not impact its operations. The company continues to advance its research and development of Alpha DaRT, an innovative cancer therapy that targets solid tumors using alpha radiation. Founded in 2016 and based in Israel, Alpha Tau Medical is focused on the commercialization of its unique treatment designed to minimize damage to surrounding healthy tissues.
Read more →DRTSAlpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update - Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received
Alpha Tau Medical announced its financial results for 2022, highlighting the launch of a U.S. pivotal trial for recurrent cutaneous squamous cell carcinoma and receiving approval from Health Canada for a liver cancer feasibility trial. The company reported a net loss of $33.8 million but maintained a cash position of $105.4 million, ensuring funding for at least the next two years. The CEO emphasized the company's focus on advancing its Alpha DaRT technology for treating various cancers and enhancing commercial efforts.
Read more →DRTS▼ -8.6%on this newsshared move
Alpha Tau Announces Alpha DaRT Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial - First two US patients with recurrent cutaneous squamous cell carcinoma have been treated a
Alpha Tau Medical Ltd. (NASDAQ: DRTS) has announced the treatment of the first two patients in its pivotal ReSTART trial, focused on recurrent cutaneous squamous cell carcinoma (cSCC). The trial, which aims to enroll up to 86 patients across the U.S., Canada, Europe, and Israel, seeks to evaluate the safety and efficacy of the Alpha DaRT treatment. The company's CEO emphasized the importance of this milestone for potential regulatory approval and the pressing need for new treatment options for patients who have exhausted other therapies.
Read more →DRTSAlpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters JERUSALEM
Alpha Tau Medical Ltd. announced the acquisition of an expanded radioactive license from the Israeli Ministry of Environmental Protection, allowing increased production of its Alpha DaRT sources from 30 milliCurie to 100 milliCurie. This change significantly enhances the facility's capacity to produce an estimated 300,000 sources annually. Additionally, the company has received regulatory approval for its pre-clinical lab, permitting experiments with mice and rats to optimize treatment combinations. This advancement aligns with Alpha Tau's ongoing expansion of clinical trials and manufacturing capabilities to meet rising demand for its cancer therapy.
Read more →DRTS▲ +7.3%on this newsshared move
Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases JERUSALEM
Alpha Tau Medical Ltd. has received Health Canada authorization to begin a feasibility and safety study of its Alpha DaRT technology for treating liver metastases. The trial will involve 10 patients at the McGill University Health Center, focusing on assessing the safety and efficacy of the radiation therapy. This marks a significant step in expanding the use of Alpha DaRT beyond current applications, potentially benefiting patients with various types of cancer.
Read more →DRTS▼ -6.1%on this news
Alpha Tau to Participate in Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference JERUSALEM
Alpha Tau Medical Ltd. (Nasdaq: DRTS) has announced its participation in Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference, scheduled for March 1, 2023, in New York City. The company is known for its innovative alpha-radiation cancer therapy, Alpha DaRT. This therapy employs radium-224 for targeted treatment of solid tumors, aiming to minimize damage to surrounding healthy tissues while effectively attacking tumors. The conference presents an opportunity for Alpha Tau to engage with potential investors and healthcare professionals.
Read more →DRTSAlpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023 JERUSALEM
Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023 December 13, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the "Company"), the develop
Read more →DRTS▼ -7.9%on this news
Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update JERUSALEM
Announces Third Quarter 2022 Financial Results and Provides Corporate Update 22, 2022 - Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , reported third quarter 2022 finan
Read more →DRTS▼ -5.7%on this news
Alpha Tau to Present at Upcoming November Investor Conferences JERUSALEM
Alpha Tau to Present at Upcoming November Investor JERUSALEM, November 9, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , today announced the Company will present
Read more →DRTSAlpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology - Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical tri
Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology - Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrooke
Read more →DRTSAlpha Tau Announces the Acceptance in Major Peer-Reviewed Journals ( International Journal of Radiation Oncology, Biology, Physics , and Frontiers in Oncology ) of Two Landmark Pre-Clinical Studies Demonstrating Signific
Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standa
Read more →DRTSAlpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer JERUSALEM
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer JERUSALEM, September 1, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , announced today that Peter Melnyk, a m
Read more →DRTSAlpha Tau Medical to Participate in Upcoming September Investor Conferences JERUSALEM
Alpha Tau Medical to Participate in Upcoming September Investor Conferences August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , today announced the Company will participate in perso
Read more →DRTS▼ -5.2%on this newsshared move
Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update -Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a
Announces Second Quarter 2022 Financial Results and Provides Corporate Update -Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial of Alpha DaRT in recurrent cutaneous squamous cell carcinoma.
Read more →DRTS▼ -5.3%on this newsshared move
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning JERUSALEM and
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning JERUSALEM and CLEVELAND, Ohio, August 22, 2022 - Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , and MIM
Read more →DRTS(NASDAQ:DRTS) Revolutionary Alpha-Emitters Radiotherapy KOL Investor Event 1 This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist
Canada - Our clinical trial strategy involves progressing our lead program (superficial tumors), particularly in the US, and conducting feasibility studies in other tumors to evaluate the Alpha DaRT in tumors of high unmet need or metastatic disease - FDA Breakthrough Device Desi
Read more →DRTS▲ +38.7%on this news
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials JERUSALEM
Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials JERUSALEM, July 5, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , announced today that it will
Read more →DRTS▲ +5%on this news
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT JERUSALEM
Alpha Tau Announces Treatment of First Prostate Cancer Patient with JERUSALEM, June 22, 2022 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , announced today that the first patient was treated in a feasibility
Read more →DRTS▲ +25.4%on this newsshared move
Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site JERUSALEM
Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site JERUSALEM, June 16, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("A
Read more →DRTSAlpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT in Recurrent Cutaneous
FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT in Recurrent Cutaneous SCC 8, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT
Read more →DRTS▼ -14.2%on this newsshared move
Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors JERUSALEM
Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , announced today that
Read more →DRTS▲ +25.7%on this news
Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update -Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gros
Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update -Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds- -Targeted start of U.S. multi-center pivotal
Read more →DRTS▲ +6.1%on this news· ran to +50% by day 3shared move
First Alpha DaRT Patients Treated in France as Part of Alpha DaRT Multicenter Skin Cancer Trial Jerusalem
First Alpha DaRT Patients Treated in France as Part of Alpha DaRT Multicenter Skin Cancer Trial May 23, 2022 - Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT , announced today that the first patients in its French multicenter tria
Read more →DRTS▲ +6.6%on this news
Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update -Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross pro
Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update -Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross proceeds- -100% complete response (CR) observed in U.S. multi-cen
Read more →DRTS▼ -7.6%on this news· ran to +36% by day 3
Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors JERUSALEM
Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors JERUSALEM, March 21, 2022 (PRNEWSWIRE) Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT , today announced the appointment of Ms. Ruth (Ruti) Alon
Read more →DRTSAlpha Tau Medical Initiates First Clinical Trial in Italy to Treat Cancer with Alpha Radiation
TEL AVIV, Israel, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Alpha Tau Medical is happy to announce its first clinical trial in Italy. The study at IRST, Meldola, will evaluate the feasibility, safety and efficacy of Alpha DaRT for the treatment of Squamous Cell Carcinoma (SCC) of the Ski
Read more →Competitive Position
How DRTS ranks across every disease it competes inCompetitive Position is a premium feature
See how DRTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial